Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)
Completed · Phase 2 · Has a placebo group
Conditions studied: Eosinophilic Esophagitis
In brief
The primary objective of the study is to assess the clinical efficacy of repeat subcutaneous (SC) doses of dupilumab, compared with placebo, to relieve symptoms in adult participants with active, moderate to severe Eosinophilic Esophagitis (EoE). The secondary objectives of the study are: * To assess the safety, tolerability, and immunogenicity of SC doses of dupilumab in adult participants with active, moderate to severe EoE * To assess the effect of dupilumab on esophageal eosinophilic infiltration * To evaluate the pharmacokinetics (PK) of dupilumab in adult participants with EoE
Key facts
- Study ID
- NCT02379052
- Run by
- Regeneron Pharmaceuticals
- People needed
- 47
- Starts
- 2015-05-12
- Expected to finish
- 2017-07-10
- Last updated by the study team
- 2020-02-28
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Study site — Idaho Falls, Idaho, United States
- Study site — Chicago, Illinois, United States
- Study site — Urbana, Illinois, United States
- Study site — Indianapolis, Indiana, United States
- Study site — Iowa City, Iowa, United States
- Study site — Chevy Chase, Maryland, United States
- Study site — Boston, Massachusetts, United States
- Study site — New York, New York, United States
- Study site — Asheville, North Carolina, United States
- Study site — Chapel Hill, North Carolina, United States
- Study site — Cincinnati, Ohio, United States
- Study site — Philadelphia, Pennsylvania, United States
- Study site — Salt Lake City, Utah, United States
- Study site — Fairfax, Virginia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.